PanCAN's Chief Scientific and Medical Officer, Dr.
@ABerkenblit, shares, "I know that in the years to come, we'll look back on this year's
#ASCO26 meeting as marking the beginning of a new era for patients with pancreatic cancer. As a long-standing American Society of Clinical Oncology (ASCO) member, it was a privilege this year to attend alongside my colleagues from Pancreatic Cancer Action Network, knowing the pivotal role PanCAN played to get us to this historic moment, and that the community is looking to PanCAN to help us all make good on the promise that RAS therapies hold for patients with pancreatic cancer.
Unprecedented indeed are the Phase 3 data for
#daraxonrasib, a RAS-targeted therapy developed by Revolution Medicines and presented by Dr. Brian Wolpin. These highly anticipated data were received with wild enthusiasm — a standing ovation! — from the ASCO community. Overall survival and progression-free survival were ~doubled, and overall response rate was ~tripled with daraxonrasib compared with chemotherapy in patients with previously treated metastatic pancreatic cancer, with all subgroups benefiting. Importantly, quality of life and pain were improved, so that patients not only live longer, but also feel better — just what we want from new therapies. Optimal management of side effects, including rash and mouth sores, is paramount to maximize the benefit — and PanCAN Patient Services is ready to embrace the educational needs!"
Learn more about the additional data released on daraxonrasib and this significant advance for
#pancreaticcancer treatment at 🔗
pcan.at/rjul9sza.
